Loading
A phase 2 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Genentech, Inc., active and no longer recruiting.
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis is a phase 2 interventional study registered as NCT06096779 by Genentech, Inc., with 30 participants enrolled, started 2024-07-15 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Roche / Genentech, Bevacizumab.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Anti-angiogenic therapy.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Hepatocellular carcinoma.